TABLE 3.
Antiviral activity of different classes of compounds against CVB3 K159 variants
| CVB3 WT or variant | EC50 (μM) (mean ± SD)a |
||
|---|---|---|---|
| T-705 | Ribavirin | Rupintrivir | |
| WT | 229 ± 24 | 254 ± 37 | 0.6 ± 0.1 |
| K159R A239G variant | 67 ± 6 (0.3)**** | 261 ± 23 | 1 ± 0.4 |
| K159M A239G variant | 116 ± 14 (0.5)*** | 198 ± 9 | 0.7 ± 0.1 |
| A239G variant | 108 ± 2 (0.5)**** | 164 ± 10 (0.6)** | 0.8 ± 0.02 |
| A372V variant | 458 ± 27 (2)**** | 419 ± 16 (1.6)**** | 0.8 ± 0.01 |
a
The values in parentheses are fold increases in resistance (EC50 for mutant/EC50 for WT), which have significant P values (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001, Student's t test). The 50% cytotoxic/cytostatic concentrations (CC50) for T-705, ribavirin, and rupintrivir were 1,773 ± 9 μM, 914 ± 2 μM, and >200 μM, respectively.